Cynosure Group LLC Grows Holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Cynosure Group LLC raised its position in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 57.6% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 32,532 shares of the company’s stock after buying an additional 11,890 shares during the period. Cynosure Group LLC’s holdings in GE HealthCare Technologies were worth $3,053,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of GEHC. LGT Financial Advisors LLC increased its position in shares of GE HealthCare Technologies by 1,673.3% during the third quarter. LGT Financial Advisors LLC now owns 266 shares of the company’s stock valued at $25,000 after acquiring an additional 251 shares during the last quarter. Ashton Thomas Securities LLC bought a new position in GE HealthCare Technologies in the 3rd quarter valued at $26,000. Pathway Financial Advisers LLC purchased a new stake in shares of GE HealthCare Technologies during the 1st quarter valued at $25,000. Capital Performance Advisors LLP purchased a new stake in shares of GE HealthCare Technologies during the 3rd quarter valued at $26,000. Finally, Darwin Wealth Management LLC bought a new stake in shares of GE HealthCare Technologies during the 3rd quarter worth $31,000. Institutional investors own 82.06% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on GEHC shares. Stifel Nicolaus increased their price target on shares of GE HealthCare Technologies from $100.00 to $102.00 and gave the company a “buy” rating in a research report on Monday, September 30th. JPMorgan Chase & Co. began coverage on shares of GE HealthCare Technologies in a research report on Monday, September 9th. They set a “neutral” rating and a $90.00 target price for the company. BTIG Research raised shares of GE HealthCare Technologies from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a report on Wednesday, September 18th. Wells Fargo & Company increased their price objective on GE HealthCare Technologies from $95.00 to $96.00 and gave the company an “overweight” rating in a report on Thursday, October 31st. Finally, Redburn Atlantic upgraded GE HealthCare Technologies to a “strong-buy” rating in a research note on Thursday, August 1st. One research analyst has rated the stock with a sell rating, five have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $94.36.

Insider Transactions at GE HealthCare Technologies

In related news, CEO Roland Rott sold 3,577 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $86.48, for a total transaction of $309,338.96. Following the transaction, the chief executive officer now directly owns 24,298 shares of the company’s stock, valued at approximately $2,101,291.04. This trade represents a 12.83 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 0.27% of the stock is currently owned by insiders.

GE HealthCare Technologies Trading Down 0.2 %

Shares of GEHC stock opened at $82.51 on Wednesday. The company has a market capitalization of $37.70 billion, a PE ratio of 22.67, a price-to-earnings-growth ratio of 2.96 and a beta of 1.24. GE HealthCare Technologies Inc. has a 52-week low of $66.39 and a 52-week high of $94.55. The business’s fifty day moving average is $88.27 and its 200 day moving average is $83.62. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.98 and a current ratio of 1.23.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.06 by $0.08. The firm had revenue of $4.86 billion during the quarter, compared to the consensus estimate of $4.87 billion. GE HealthCare Technologies had a return on equity of 25.19% and a net margin of 8.56%. The company’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter last year, the company posted $0.99 EPS. On average, equities research analysts anticipate that GE HealthCare Technologies Inc. will post 4.3 EPS for the current fiscal year.

GE HealthCare Technologies Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Tuesday, January 14th will be given a dividend of $0.035 per share. The ex-dividend date is Tuesday, January 14th. This represents a $0.14 annualized dividend and a dividend yield of 0.17%. This is a boost from GE HealthCare Technologies’s previous quarterly dividend of $0.03. GE HealthCare Technologies’s dividend payout ratio (DPR) is 3.30%.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.